Placebo: a potent but misunderstood psychotrope.
作者信息
Lapierre Y D
出版信息
J Psychiatry Neurosci. 1995 May;20(3):173-4.
Abstract
摘要
相似文献
1
Placebo: a potent but misunderstood psychotrope.安慰剂：一种强效但被误解的精神药物。
J Psychiatry Neurosci. 1995 May;20(3):173-4.
2
3
Pharmacotherapy of anxious disorders.焦虑症的药物治疗。
Hum Psychopharmacol. 2002 Dec;17(8):383-400. doi: 10.1002/hup.435.
4
Let's talk facts about anxiety disorders.让我们谈谈焦虑症的实际情况。
J Okla State Med Assoc. 2008 Dec;101(12):347-50.
5
Recent advances in the understanding and treatment of anxiety disorders.焦虑症理解与治疗的最新进展
Prim Care. 2007 Sep;34(3):475-504, v-vi. doi: 10.1016/j.pop.2007.05.002.
6
Are placebo-controlled trials still important for obsessive compulsive disorder?
Prog Neuropsychopharmacol Biol Psychiatry. 2006 May;30(3):413-22. doi: 10.1016/j.pnpbp.2005.11.012. Epub 2006 Jan 18.
7
Anxiety disorders in schizophrenia.精神分裂症中的焦虑障碍
Compr Psychiatry. 2004 Nov-Dec;45(6):460-8. doi: 10.1016/j.comppsych.2004.07.009.
8
[Treatment of neurosis and placebo effect].
Schweiz Arch Neurol Neurochir Psychiatr. 1973;113(2):357-68.
9
Management of comorbid anxiety and depression.共病焦虑和抑郁的管理。
J Clin Psychiatry. 1995;56 Suppl 2:10-3.
10
The effect of anxiety disorder comorbidity on treatment resistant bipolar disorders.焦虑症共病对难治性双相情感障碍的影响。
Depress Anxiety. 2008;25(2):91-7. doi: 10.1002/da.20279.
本文引用的文献
1
A comparison of fluvoxamine, cognitive therapy, and placebo in the treatment of panic disorder.氟伏沙明、认知疗法与安慰剂治疗惊恐障碍的比较。
Arch Gen Psychiatry. 1993 Jan;50(1):44-50. doi: 10.1001/archpsyc.1993.01820130046008.
2
The continuing unethical use of placebo controls.安慰剂对照的持续不道德使用。
N Engl J Med. 1994 Aug 11;331(6):394-8. doi: 10.1056/NEJM199408113310611.
3
Use of placebo controls in clinical trials disputed.临床试验中安慰剂对照的使用存在争议。
Science. 1995 Jan 6;267(5194):25-6. doi: 10.1126/science.7809605.
4
[Mesoridazine therapy in neurotics-clinical trial].[甲硫哒嗪治疗神经症——临床试验]
Union Med Can. 1972 Aug;101(8):1509-12.
5
Methods of evaluation of psychoactive drugs.精神活性药物的评估方法。
Recenti Prog Med. 1989 Dec;80(12):706-11.
6
Relevance of DMS-III depressive subtype and chronicity of antidepressant efficacy in atypical depression. Differential response to phenelzine, imipramine, and placebo.DMS-III抑郁亚型与非典型抑郁症中抗抑郁药疗效的慢性相关性。对苯乙肼、丙咪嗪和安慰剂的差异反应。
Arch Gen Psychiatry. 1989 Dec;46(12):1080-7. doi: 10.1001/archpsyc.1989.01810120022005.
7
Clomipramine and obsessive compulsive disorder: a placebo-controlled double-blind study of 32 patients.氯米帕明与强迫症：一项针对32名患者的安慰剂对照双盲研究。
J Clin Psychiatry. 1990 Jul;51(7):292-7.
8
A placebo-controlled clinical trial of remoxipride and chlorpromazine in newly admitted schizophrenic patients with acute exacerbation.雷莫必利与氯丙嗪治疗新入院急性加重期精神分裂症患者的安慰剂对照临床试验。
Acta Psychiatr Scand Suppl. 1990;358:111-9. doi: 10.1111/j.1600-0447.1990.tb05301.x.
9
Discontinuation of neuroleptic medication in older, outpatient schizophrenics. A placebo-controlled, double-blind trial.老年门诊精神分裂症患者停用抗精神病药物治疗：一项安慰剂对照双盲试验。
J Nerv Ment Dis. 1991 Apr;179(4):212-4. doi: 10.1097/00005053-199104000-00006.
10
Increased motor activity and recurrent manic episodes: predictors of rapid relapse in remitted bipolar disorder patients after lithium discontinuation.运动活动增加和复发性躁狂发作：双相情感障碍缓解期患者停用锂盐后快速复发的预测因素。
Biol Psychiatry. 1992 Feb 1;31(3):279-84. doi: 10.1016/0006-3223(92)90051-z.
Zotero 插件